255 related articles for article (PubMed ID: 5007259)
1. Drug product equivalence--are specifications necessary?
Bergen JV
J Am Pharm Assoc; 1972 Jan; 12(1):21-5. PubMed ID: 5007259
[No Abstract] [Full Text] [Related]
2. [The role of biopharmaceutical parameters in drug development (author's transl)].
Thoma K
Arzneimittelforschung; 1976; 26(1A):121-9. PubMed ID: 947191
[TBL] [Abstract][Full Text] [Related]
3. New York State and drug lists: a history of confusion.
Stetler CJ
Med Mark Media; 1978 Sep; 13(9):36, 38, 40 passim. PubMed ID: 10316687
[No Abstract] [Full Text] [Related]
4. How good are our drugs?
Miller LC
Am J Hosp Pharm; 1970 May; 27(5):367-74. PubMed ID: 5422276
[No Abstract] [Full Text] [Related]
5. Product dissolution methods: response.
Tingstad JE
J Pharm Sci; 1973 Jul; 62(7):VI. PubMed ID: 4714144
[No Abstract] [Full Text] [Related]
6. The importance of drug standards.
Heller WM
Am J Hosp Pharm; 1982 Apr; 39(4):652-3. PubMed ID: 7081247
[No Abstract] [Full Text] [Related]
7. Drug product equivalence--the problem, the challenge and the USP.
Macek TJ
J Am Pharm Assoc; 1972 Jan; 12(1):26-8. PubMed ID: 5007260
[No Abstract] [Full Text] [Related]
8. "Who shall establish drug standards"?
Macek TJ
J Am Pharm Assoc; 1973 Mar; 13(3):122-3. PubMed ID: 4689929
[No Abstract] [Full Text] [Related]
9. USP standards for dissolution and bioavailability.
Grady LT
Am J Hosp Pharm; 1982 Sep; 39(9):1546-8. PubMed ID: 7137198
[No Abstract] [Full Text] [Related]
10. [Evaluation of the physiological availability of drug substances in capsules].
Mikhaĭlova GS
Farmatsiia; 1975; 24(1):78-82. PubMed ID: 770209
[No Abstract] [Full Text] [Related]
11. Drug product equivalence--the problem, the challenge, and the U.S.P.
Macek TJ
Am J Pharm Sci Support Public Health; 1971; 143(6):188-94. PubMed ID: 5140167
[No Abstract] [Full Text] [Related]
12. Drug standards laboratory enters second decade.
Reese KM
J Am Pharm Assoc; 1972 Jan; 12(1):16-20. PubMed ID: 5007258
[No Abstract] [Full Text] [Related]
13. The official compendia.
Macek TJ
Pharmacology; 1972; 8(1):204-6. PubMed ID: 4644650
[No Abstract] [Full Text] [Related]
14. Quality drugs and the Saskatchewan formulary.
Johnson GE
Can J Hosp Pharm; 1975; 28(3):84-6. PubMed ID: 10316621
[No Abstract] [Full Text] [Related]
15. Equivalence studies for complex active ingredients and dosage forms.
Bhattycharyya L; Dabbah R; Hauck W; Sheinin E; Yeoman L; Williams R
AAPS J; 2005 Nov; 7(4):E786-812. PubMed ID: 16594632
[TBL] [Abstract][Full Text] [Related]
16. Drug product quality--views of the regulators. USP/NF: public standards for drug product quality.
Grady LT
J Am Pharm Assoc; 1976 Nov; 16(11):603-4. PubMed ID: 977885
[No Abstract] [Full Text] [Related]
17. [ICH4 and pharmacopoeias: similarities and differences].
Artiges A
Ann Pharm Fr; 1999 Mar; 57(2):161-7. PubMed ID: 10365473
[TBL] [Abstract][Full Text] [Related]
18. [Clinical testing of drugs].
Elis J
Cesk Zdrav; 1973; 21(3):126-30. PubMed ID: 4580127
[No Abstract] [Full Text] [Related]
19. [The new drug formulary (NDF) of the German drug codex].
Reimann H
Pharm Unserer Zeit; 2010 Jul; 39(4):274-9. PubMed ID: 20589798
[No Abstract] [Full Text] [Related]
20. Role of the compendia in controlling factors affecting bioavailability of drug products.
Blake MI
J Am Pharm Assoc; 1971 Nov; 11(11):603-11. PubMed ID: 5133104
[No Abstract] [Full Text] [Related]
[Next] [New Search]
